Frailty and chronic kidney disease: associations and implications

ABSTRACT Introduction: Frailty and its association with chronic kidney disease (CKD) has been established previously. The present study examined this association further by studying the distribution of frailty among groups defined by different stages of the disease. It also identified associated health deficits and explored their association with estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR). Methods: A cross-sectional survey was conducted on 90 non-dialysis dependent CKD Stage 1–4 patients, recruited in three stratified groups of 30 participants each based on the stage of disease. Frailty was assessed using Fried’s frailty criteria and associated health deficits were recorded using a pre-determined list. Depression was screened using a 4-point depression scale. Results: 21.1% of the participants were frail and 43.3% were pre-frail. The proportion of frailty in CKD groups A (Stages 1 and 2), B (Stage 3a), and C (Stages 3b and 4) was 10%, 13.3%, and 40%, respectively. The association of health deficits including co-morbidities, physical parameters, mental status, daily activities, etc. with UACR, eGFR, and CKD stages was not statistically significant. Nearly one in two frail participants was depressed compared with 14% among non-frail participants. Conclusion: The skewed distribution of 21% frail subjects identified in our study indicates an association between frailty and advancing kidney disease. Frail individuals had a lower eGFR, higher UACR, were more likely to be depressed, and had higher count of health deficits and poorer performance on Barthel Index of Activities of Daily Living and WHOQOL. Early identification of depression would improve care in these patients

Eurasian consumers' food safety beliefs and trust issues in the age of COVID ‐19: evidence from an online survey in 15 countries

Eurasian consumers' food safety beliefs and trust issues in the age of COVID ‐19: evidence from an online survey in 15 countries Igor Tomasevic Faculty of Agriculture University of Belgrade Belgrade Serbia German Institute of Food Technologies (DIL) Quakenbrück Germany Department of Dairy Technology and Functional Foods, Faculty of Food Sciences and Biotechnology University of Life Sciences in Lublin Lublin Poland https://orcid.org/0000-0002-1611-2264 Garegin Hambardzumyan Armenian National Agrarian University Yerevan Armenia Gayane Marmaryan Armenian National Agrarian University Yerevan Armenia Aleksandra Nikolic Faculty of Agriculture and Food Sciences University of Sarajevo Sarajevo Bosnia and Herzegovina Alen Mujcinovic Faculty of Agriculture and Food Sciences University of Sarajevo Sarajevo Bosnia and Herzegovina Weizheng Sun School of Food Science and Engineering South China University of Technology Guangzhou China https://orcid.org/0000-0001-5769-4275 Xiao‐Chen Liu School of Food Science and Engineering South China University of Technology Guangzhou China Danijela Bursać Kovačević Faculty of Food Technology and Biotechnology University of Zagreb Zagreb Croatia Anica Bebek Markovinović Faculty of Food Technology and Biotechnology University of Zagreb Zagreb Croatia Nino Terjung German Institute of Food Technologies (DIL) Quakenbrück Germany Volker Heinz German Institute of Food Technologies (DIL) Quakenbrück Germany Maria Papageorgiou Department of Food Science and Technology International Hellenic University Thessaloniki Greece Adriana Skendi Department of Food Science and Technology International Hellenic University Thessaloniki Greece Gunjan Goel Department of Microbiology Central University of Haryana Mahendragarh India https://orcid.org/0000-0002-8761-929X Mamta Raghav Department of Life Sciences RPS Degree College Mahendragarh India Antonella Dalle Zotte Department of Animal Medicine, Production and Health University of Padova Padova Italy Dimitar Nakov Faculty of Agriculture "Goce Delcev" University in Stip Shtip Republic of North Macedonia Faculty of Medical Sciences "Goce Delcev" University in Stip Shtip Republic of North Macedonia Valentina Velkoska Faculty of Agriculture "Goce Delcev" University in Stip Shtip Republic of North Macedonia Bartosz G. Sołowiej Department of Dairy Technology and Functional Foods, Faculty of Food Sciences and Biotechnology University of Life Sciences in Lublin Lublin Poland Anastasia A. Semenova V. M. Gorbatov Federal Research Center for Food Systems Moscow Russia Oksana A. Kuznetsova V. M. Gorbatov Federal Research Center for Food Systems Moscow Russia Miroslav Krocko Department of Technology and Quality of Animal Products, Faculty of Biotechnology and Food Sciences Institute of Food Sciences, Slovak University of Agriculture in Nitra Nitra Slovakia Viera Duckova Department of Technology and Quality of Animal Products, Faculty of Biotechnology and Food Sciences Institute of Food Sciences, Slovak University of Agriculture in Nitra Nitra Slovakia Jose M. Lorenzo Centro Tecnológico de la Carne de Galicia Ourense Spain https://orcid.org/0000-0002-7725-9294 Noemi Echegaray Centro Tecnológico de la Carne de Galicia Ourense Spain https://orcid.org/0000-0002-7393-2955 Emel Oz Department of Food Engineering, Agriculture Faculty Atatürk University Erzurum Türkiye https://orcid.org/0000-0003-3766-2713 Fatih Oz Department of Food Engineering, Agriculture Faculty Atatürk University Erzurum Türkiye https://orcid.org/0000-0002-5300-7519 Ilija Djekic Faculty of Agriculture University of Belgrade Belgrade Serbia Abstract BACKGROUND This investigation provides an important insight into Eurasian consumers' food safety beliefs and trust issues influenced by the COVID‐19 pandemic. An online survey was conducted in 15 European and Asian countries involving more than 4000 consumers. RESULTS It has confirmed that different socioeconomic characteristics, cultural aspects and education levels shape food safety perceptions within Eurasian countries. The COVID‐19 pandemic influenced their beliefs and trust in food safety, which is relatively low on average. However, it is significantly higher for European consumers (especially European Union ones) compared to their Asian counterparts. Both Asian and European respondents agreed that food fraud and climate changes represent a food safety issue. However, European consumers were less concerned regarding the food safety of genetically modified foods and meat and dairy analogs/hybrids. Asian consumers were, to a greater extent, worried about the risk of getting COVID‐19 from food, restaurants, food retail establishments and home food deliveries. CONCLUSION Eurasian consumers have put their greatest extent of trust, when food safety assurance is concerned, into food scientists and food producers holding a food safety certificate. Broadly, they are uncertain to what extent their federal governments and food inspectors are competent, able and efficient in ensuring food safety. Higher education of Eurasian consumers was followed by increased food safety confidence in all parts of the food chain. © 2023 The Authors. Journal of The Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry. 07 13 2023 jsfa.12815 10.1002/jsfa.12815 2 10.1002/crossmark_policy onlinelibrary.wiley.com true 2023-02-27 2023-06-21 2023-07-13 http://creativecommons.org/licenses/by-nc-nd/4.0/ 10.1002/jsfa.12815 https://onlinelibrary.wiley.com/doi/10.1002/jsfa.12815 https://onlinelibrary.wiley.com/doi/pdf/10.1002/jsfa.12815 10.1097/PHH.0000000000001470 10.4315/JFP-21-096 10.1186/s12889-022-12568-4 10.1007/s10551-015-2690-5 10.1037/ipp0000074 10.1007/BF02249397 10.1016/j.foodqual.2017.09.012 10.1093/heapro/daw024 10.1016/S0195-6663(03)00112-0 10.1080/18692729.2017.1256987 10.1080/15287394.2016.1174008 10.1016/B978-0-12-381504-0.00041-X 10.1016/j.foodcont.2020.107800 Studies in Systems, Decision and Control Azzam Z 25 10.1016/j.appet.2021.105309 10.2139/ssrn.4053920 LimA XuJandYuYeds Consumer Food Demand Shifts in the COVID‐19 Pandemic: An Empirical Study Based on Retail Sales Data. Lecture Notes in Networks and Systems; 2023 Consumer Food Demand Shifts in the COVID‐19 Pandemic: An Empirical Study Based on Retail Sales Data. 10.3390/math10091394 Econ Pol Wkly Kaicker N 16 57 2022 Food consumption expenditures and the COVID‐19 pandemic in India 10.1016/j.appet.2022.106313 10.1016/j.foodcont.2020.107089 10.3390/foods11030432 10.1016/j.foodcont.2020.107238 10.1016/j.tifs.2003.08.004 Kodeks profesionalne etike Univerziteta u Beogradu Serbia 193 2016 10.1111/j.1365-2648.2004.03185.x 10.1016/j.foodcont.2022.109216 10.1016/j.appet.2022.106265 10.1016/B978-0-12-813148-0.00001-3 Basic statistics: a modern approach Hamburg M 548 1985 Fundamentals of Biostatistics Rosner B 2011 10.1016/j.jretconser.2011.08.007 10.1108/00070700210418767 Ageing Europe: looking at the lives of older people in the EU:2 020th edition Eurostat 2020 CIA Median Age‐The World Factbook: Central Intelligence Agency(2022). Available from:https://www.cia.gov/the-world-factbook/field/median-age/country-comparison. 10.1016/j.jpolmod.2015.05.002 Higher education across asia: an overview of issues and strategies ADB 66 2011 10.1016/j.tifs.2019.10.005 Rapid alert system for food and feed‐alert and cooperation network: 2021 annual report RASFF 2021 10.1016/j.foodres.2016.08.028 10.1007/s13593-022-00778-4 BhavanaTandRoshanD Europe meat substitute market by product type source and category: regional opportunity analysis and industry forecast 2021‐2027 allied market research(2021). Nils‐GerritW Plant‐based milk and dairy alternatives in Europe‐statistics & facts: Statista(2022). Available from:https://www.statista.com/topics/10162/milk-and-dairy-alternatives-in-europe/#topicOverview. Nils‐GerritW Retail sales value of milk and milk alternatives worldwide in 2020 by region: Statista(2021). Available from:https://www.statista.com/topics/10162/milk-and-dairy-alternatives-in-europe/#topicOverview. 10.1016/j.appet.2011.06.010 10.1007/978-3-030-12453-3_53 10.1108/CAER-08-2015-0102 10.1111/ijcs.12345 10.1371/journal.pone.0126060 10.1080/14636778.2012.743269 10.1016/j.meatsci.2019.107965 10.1016/j.tifs.2013.01.003 Coronavirus: no Evidence that Food Is a Source or Transmission Route EFSA 2020 10.1016/S0140-6736(20)30211-7 10.1016/j.foodcont.2015.07.028 10.1016/j.ijhm.2021.102960 10.1016/j.ijhm.2021.102988 10.1016/j.jretconser.2022.102972 10.1016/j.ijhm.2020.102821 10.1016/j.ijgfs.2021.100330 10.1016/j.gfs.2022.100658 10.1016/j.meatsci.2015.12.008 10.1016/j.tifs.2020.08.020 10.1111/ijcs.12184 EFSA Food Safety in the EU: report(2022). 10.3390/foods10102490 10.4102/hsag.v26i0.1407 10.1016/j.foodcont.2022.109377 10.1016/j.foodcont.2013.11.022 10.1016/j.ijhm.2021.102905 10.1002/agr.21414 10.1016/j.fct.2020.111170 10.1016/j.appet.2004.05.003 10.1016/j.jneb.2018.03.013 10.1016/j.emj.2017.02.00

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Understanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice. To systematically quantify the contributions of risk factor exposures to specific health outcomes, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 aims to provide comprehensive estimates of exposure levels, relative health risks, and attributable burden of disease for 88 risk factors in 204 countries and territories and 811 subnational locations, from 1990 to 2021. Methods: The GBD 2021 risk factor analysis used data from 54 561 total distinct sources to produce epidemiological estimates for 88 risk factors and their associated health outcomes for a total of 631 risk–outcome pairs. Pairs were included on the basis of data-driven determination of a risk–outcome association. Age-sex-location-year-specific estimates were generated at global, regional, and national levels. Our approach followed the comparative risk assessment framework predicated on a causal web of hierarchically organised, potentially combinative, modifiable risks. Relative risks (RRs) of a given outcome occurring as a function of risk factor exposure were estimated separately for each risk–outcome pair, and summary exposure values (SEVs), representing risk-weighted exposure prevalence, and theoretical minimum risk exposure levels (TMRELs) were estimated for each risk factor. These estimates were used to calculate the population attributable fraction (PAF; ie, the proportional change in health risk that would occur if exposure to a risk factor were reduced to the TMREL). The product of PAFs and disease burden associated with a given outcome, measured in disability-adjusted life-years (DALYs), yielded measures of attributable burden (ie, the proportion of total disease burden attributable to a particular risk factor or combination of risk factors). Adjustments for mediation were applied to account for relationships involving risk factors that act indirectly on outcomes via intermediate risks. Attributable burden estimates were stratified by Socio-demographic Index (SDI) quintile and presented as counts, age-standardised rates, and rankings. To complement estimates of RR and attributable burden, newly developed burden of proof risk function (BPRF) methods were applied to yield supplementary, conservative interpretations of risk–outcome associations based on the consistency of underlying evidence, accounting for unexplained heterogeneity between input data from different studies. Estimates reported represent the mean value across 500 draws from the estimate's distribution, with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values across the draws. Findings: Among the specific risk factors analysed for this study, particulate matter air pollution was the leading contributor to the global disease burden in 2021, contributing 8·0% (95% UI 6·7–9·4) of total DALYs, followed by high systolic blood pressure (SBP; 7·8% [6·4–9·2]), smoking (5·7% [4·7–6·8]), low birthweight and short gestation (5·6% [4·8–6·3]), and high fasting plasma glucose (FPG; 5·4% [4·8–6·0]). For younger demographics (ie, those aged 0–4 years and 5–14 years), risks such as low birthweight and short gestation and unsafe water, sanitation, and handwashing (WaSH) were among the leading risk factors, while for older age groups, metabolic risks such as high SBP, high body-mass index (BMI), high FPG, and high LDL cholesterol had a greater impact. From 2000 to 2021, there was an observable shift in global health challenges, marked by a decline in the number of all-age DALYs broadly attributable to behavioural risks (decrease of 20·7% [13·9–27·7]) and environmental and occupational risks (decrease of 22·0% [15·5–28·8]), coupled with a 49·4% (42·3–56·9) increase in DALYs attributable to metabolic risks, all reflecting ageing populations and changing lifestyles on a global scale. Age-standardised global DALY rates attributable to high BMI and high FPG rose considerably (15·7% [9·9–21·7] for high BMI and 7·9% [3·3–12·9] for high FPG) over this period, with exposure to these risks increasing annually at rates of 1·8% (1·6–1·9) for high BMI and 1·3% (1·1–1·5) for high FPG. By contrast, the global risk-attributable burden and exposure to many other risk factors declined, notably for risks such as child growth failure and unsafe water source, with age-standardised attributable DALYs decreasing by 71·5% (64·4–78·8) for child growth failure and 66·3% (60·2–72·0) for unsafe water source. We separated risk factors into three groups according to trajectory over time: those with a decreasing attributable burden, due largely to declining risk exposure (eg, diet high in trans-fat and household air pollution) but also to proportionally smaller child and youth populations (eg, child and maternal malnutrition); those for which the burden increased moderately in spite of declining risk exposure, due largely to population ageing (eg, smoking); and those for which the burden increased considerably due to both increasing risk exposure and population ageing (eg, ambient particulate matter air pollution, high BMI, high FPG, and high SBP). Interpretation: Substantial progress has been made in reducing the global disease burden attributable to a range of risk factors, particularly those related to maternal and child health, WaSH, and household air pollution. Maintaining efforts to minimise the impact of these risk factors, especially in low SDI locations, is necessary to sustain progress. Successes in moderating the smoking-related burden by reducing risk exposure highlight the need to advance policies that reduce exposure to other leading risk factors such as ambient particulate matter air pollution and high SBP. Troubling increases in high FPG, high BMI, and other risk factors related to obesity and metabolic syndrome indicate an urgent need to identify and implement interventions

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Abstract: The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era

Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020

Background The health risks associated with moderate alcohol consumption continue to be debated. Small amounts of alcohol might lower the risk of some health outcomes but increase the risk of others, suggesting that the overall risk depends, in part, on background disease rates, which vary by region, age, sex, and year. Methods For this analysis, we constructed burden-weighted dose–response relative risk curves across 22 health outcomes to estimate the theoretical minimum risk exposure level (TMREL) and non-drinker equivalence (NDE), the consumption level at which the health risk is equivalent to that of a non-drinker, using disease rates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020 for 21 regions, including 204 countries and territories, by 5-year age group, sex, and year for individuals aged 15–95 years and older from 1990 to 2020. Based on the NDE, we quantified the population consuming harmful amounts of alcohol. Findings The burden-weighted relative risk curves for alcohol use varied by region and age. Among individuals aged 15–39 years in 2020, the TMREL varied between 0 (95% uncertainty interval 0–0) and 0·603 (0·400–1·00) standard drinks per day, and the NDE varied between 0·002 (0–0) and 1·75 (0·698–4·30) standard drinks per day. Among individuals aged 40 years and older, the burden-weighted relative risk curve was J-shaped for all regions, with a 2020 TMREL that ranged from 0·114 (0–0·403) to 1·87 (0·500–3·30) standard drinks per day and an NDE that ranged between 0·193 (0–0·900) and 6·94 (3·40–8·30) standard drinks per day. Among individuals consuming harmful amounts of alcohol in 2020, 59·1% (54·3–65·4) were aged 15–39 years and 76·9% (73·0–81·3) were male. Interpretation There is strong evidence to support recommendations on alcohol consumption varying by age and location. Stronger interventions, particularly those tailored towards younger individuals, are needed to reduce the substantial global health loss attributable to alcohol. Funding Bill & Melinda Gates Foundation

Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021

Background: Smoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and although strategies have recently been proposed to achieve tobacco-free generations, none have been implemented to date. Assessing what could happen if current trends in smoking prevalence persist, and what could happen if additional smoking prevalence reductions occur, is important for communicating the effect of potential smoking policies. Methods: In this analysis, we use the Institute for Health Metrics and Evaluation's Future Health Scenarios platform to forecast the effects of three smoking prevalence scenarios on all-cause and cause-specific YLLs and life expectancy at birth until 2050. YLLs were computed for each scenario using the Global Burden of Disease Study 2021 reference life table and forecasts of cause-specific mortality under each scenario. The reference scenario forecasts what could occur if past smoking prevalence and other risk factor trends continue, the Tobacco Smoking Elimination as of 2023 (Elimination-2023) scenario quantifies the maximum potential future health benefits from assuming zero percent smoking prevalence from 2023 onwards, whereas the Tobacco Smoking Elimination by 2050 (Elimination-2050) scenario provides estimates for countries considering policies to steadily reduce smoking prevalence to 5%. Together, these scenarios underscore the magnitude of health benefits that could be reached by 2050 if countries take decisive action to eliminate smoking. The 95% uncertainty interval (UI) of estimates is based on the 2·5th and 97·5th percentile of draws that were carried through the multistage computational framework. Findings: Global age-standardised smoking prevalence was estimated to be 28·5% (95% UI 27·9–29·1) among males and 5·96% (5·76–6·21) among females in 2022. In the reference scenario, smoking prevalence declined by 25·9% (25·2–26·6) among males, and 30·0% (26·1–32·1) among females from 2022 to 2050. Under this scenario, we forecast a cumulative 29·3 billion (95% UI 26·8–32·4) overall YLLs among males and 22·2 billion (20·1–24·6) YLLs among females over this period. Life expectancy at birth under this scenario would increase from 73·6 years (95% UI 72·8–74·4) in 2022 to 78·3 years (75·9–80·3) in 2050. Under our Elimination-2023 scenario, we forecast 2·04 billion (95% UI 1·90–2·21) fewer cumulative YLLs by 2050 compared with the reference scenario, and life expectancy at birth would increase to 77·6 years (95% UI 75·1–79·6) among males and 81·0 years (78·5–83·1) among females. Under our Elimination-2050 scenario, we forecast 735 million (675–808) and 141 million (131–154) cumulative YLLs would be avoided among males and females, respectively. Life expectancy in 2050 would increase to 77·1 years (95% UI 74·6–79·0) among males and 80·8 years (78·3–82·9) among females. Interpretation: Existing tobacco policies must be maintained if smoking prevalence is to continue to decline as forecast by the reference scenario. In addition, substantial smoking-attributable burden can be avoided by accelerating the pace of smoking elimination. Implementation of new tobacco control policies are crucial in avoiding additional smoking-attributable burden in the coming decades and to ensure that the gains won over the past three decades are not lost